En Es
Categories

Industry News

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

By Labmedica International staff writers
13 Jan 2021

Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient.

The image analysis algorithms use artificial intelligence (AI) to support pathologists in making faster, more accurate patient diagnoses in breast cancer. A mutation in the HER2 gene, which occurs in as many as 20% of the 2.1 million cases of breast cancer diagnosed globally each year, is responsible for aggressive growth in some patients. Identifying this mutation is important in determining which patients may benefit from targeted treatment. uPath HER2 (4B5) image analysis for breast cancer helps pathologists to quickly determine whether tumors are positive for the HER2 biomarker, highlighting positively stained tumor cell membranes with a clear visual overlay for easy reference.

uPath HER2 Dual ISH image analysis for breast cancer assists the pathologist in the determination of HER2 gene amplification. A heatmap is provided to guide pathologists to areas of interest where the algorithm can identify cells to inform the determination of a treatment strategy. Validated on the VENTANA HER2 (4B5) assay and the VENTANA HER2 Dual ISH DNA Probe Cocktail, the algorithms are ready-to-use and integrated within the Roche uPath enterprise software.

The uPath HER2 (4B5) image analysis and uPath HER2 Dual ISH image analysis algorithms for breast cancer expand Roche’s digital pathology portfolio to empower precision diagnosis. The uPath image analysis algorithm suite for pathology decision support offers ready-to-use image analysis tools, providing fast, consistent and automated analysis so that pathologists can quickly, accurately and confidently assess immunohistochemistry and in situ hybridization. All algorithms in the suite for uPath software will provide image analysis of VENTANA DP 200 scanned slide images stained with a Roche Tissue Diagnostics assay.

“About 15 to 20% of women diagnosed with breast cancer are HER2 positive, which makes fast and accurate diagnosis critical,” said Thomas Schinecker, CEO Roche Diagnostics. “Roche is continuing to innovate in HER2 diagnostics by providing precise information through image analysis algorithms for pathology decision support.”






E-mail Print
FaceBook Twitter Google+ Linked in

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests
More info

More articles about Roche Diagnostics

16 Mar 2021
Roche to Acquire Genmark Diagnostics to Access Novel Technology to Test for Pathogens with One Patient Sample
Roche (Basel, Switzerland) and GenMark Diagnostics, Inc. (Carlsbad, CA, USA) have entered into a definitive merger agreement for Roche to fully acquire GenMark which provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample.
Read More
26 Jan 2021
Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions
Under the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment to their long standing Distribution, Sales and Service (DSS) agreement, allowing Roche to continue to distribute Sysmex hematology products, including instruments and reagents.
Read More
18 Oct 2018
Roche Launches Roche Healthcare Consulting
Roche (Basel, Switzerland) has launched Roche Healthcare Consulting, a specialized consulting service that aims to help leaders in laboratories, hospitals and other healthcare groups optimize their operational, clinical and financial performance.
Read More

Additional news

19 Apr 2021
Siemens Completes Acquisition of Varian to Create Integrated Portfolio of Imaging, Laboratory Diagnostics, AI and Cancer Treatment
Siemens Healthineers (Erlangen, Germany) has successfully completed the acquisition of Varian Medical Systems, Inc. (Palo Alto, CA, USA), thus strengthening its position as a holistic partner in healthcare.
Read More
16 Apr 2021
Eppendorf Introduces Multipurpose Centrifuge 5910 Ri to Accelerate Results
Eppendorf AG (Hamburg, Germany) has introduced a new centrifuge designed to increase efficiency in the laboratory, Centrifuge 5910 Ri, a successor to the company’s popular Centrifuge 5910 R.
Read More
16 Apr 2021
Artificial Intelligence (AI) in Medical Diagnostics Market to Reach USD 3.86 Billion by 2025
The global Artificial Intelligence (AI) in Medical Diagnostics Market is projected to grow at a CAGR of 50.2% from USD 0.5 billion in 2020 to USD 3.86 billion by 2025, driven primarily by government initiatives to increase the adoption of AI-based technologies, increasing demand for AI tools in the medical field, growing focus on reducing the workload of radiologists, influx of large and complex datasets, growth in funding for AI-based start-ups, and growing number of cross-industry partnerships and collaborations.
Read More
15 Apr 2021
Microsoft Acquires Radiology Vendor Nuance to Deliver New Cloud and AI Capabilities Across Healthcare
Microsoft Corporation (Redmond, WA, USA) will acquire Nuance Communications, Inc. (Burlington, MA, USA) in an all-cash transaction valued at USD 19.7 billion to combine their solutions and expertise that will deliver new cloud and AI capabilities across healthcare and other industries.
Read More
14 Apr 2021
Zoll Medical Acquires CSA Systems Manufacturer Respicardia
 ZOLL Medical Corporation (Chelmsford, MA, USA), an Asahi Kasei company, has acquired Respicardia, Inc. (Minnetonka, MN, USA), a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA).
Read More
13 Apr 2021
DiaSorin to Acquire Luminex to Broaden Positioning in Molecular Diagnostics Space
DiaSorin S.p.A. (?Saluggia?, Italy) has announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (Austin, TX, USA) for approximately USD 1.8 billion.
Read More
13 Apr 2021
Philips Collaborates with AI Startup Ibex to Accelerate Adoption of AI-Powered Digital Pathology Solutions
Royal Philips (Amsterdam, The Netherlands) and Ibex Medical Analytics (Tel Aviv, Israel) have entered into a strategic collaboration to jointly promote their digital pathology and AI solutions to hospitals, health networks and pathology labs worldwide.
Read More
09 Apr 2021
Rapid AI Penetration to Drive Growth of Global MR Vital Sign Monitors Market
A surge in cases of chronic obstructive pulmonary disease (COPD) and cardiovascular diseases is encouraging clinicians and manufacturers to develop artificial intelligence (AI)-driven MR vital sign monitors, thereby driving the growth of the global MR vital sign monitors market.
Read More
09 Apr 2021
Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business
Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated molecular platform, which offers ease of use, multiplex capability and rapid turnaround time.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions